"Saphyr,” says McCarthy, “Could potentially replace these techniques with a simplified and rapid automated workflow that provides comprehensive detection regardless of the type of variation. Saphyr’s workflow is much quicker, running 42 samples in a week… As such, the Saphyr approach could set the stage to integrate into the cytogenetics labs.”
To this end, McCarthy rates BNGO a Buy along with a $2 price target. Investors could be pocketing a hefty 155% gain, should McCarthy’s thesis play out in the year ahead. (To watch McCarthy’s track record, click here)
With the addition of 2 more Buy ratings posted over the last 3 months, BNGO has a Strong Buy consensus rating. The average price target is $1.47, and while not quite
News 
Market Data 
Discover 
AI
